ASND Form 144: Insider sale notice for 2,158 shares

Rhea-AI Filing Summary

Ascendis Pharma A/S (ASND) filed a Form 144 reporting a proposed sale of 2,158 ordinary shares. The filing lists an aggregate market value of 412,319.34 and 60,454,589 shares outstanding. The shares are to be sold on NASDAQ with an approximate sale date of 08/13/2025.

The securities were acquired on 08/13/2025 through Restricted Stock Vesting from Ascendis Pharma A/S and the payment nature is listed as Compensation. The filing indicates no securities sold during the past three months and includes the standard signature representation that the seller does not possess undisclosed material adverse information. The form does not name the person for whose account the securities are to be sold.

Insights

Securities Analyst

TL;DR: Small planned sale—2,158 shares represent approximately 0.0036% of outstanding stock, so market impact is likely negligible.

The Form 144 notifies the market of a proposed sale of 2,158 shares with an aggregate value of 412,319.34. Relative to the stated 60,454,589 shares outstanding, the lot equals about 0.0036% of the float, indicating the sale is immaterial from a supply-demand perspective. The securities were acquired via restricted stock vesting on the same date and the payment is listed as compensation, consistent with routine insider monetization following vesting. No prior sales in the past three months are reported.

Corporate Governance Expert

TL;DR: Filing appears compliant and routine; it discloses the vesting-origin and contains the required representations about material nonpublic information.

The Form 144 includes required disclosure elements: class of security, broker name, number of shares, aggregate market value, acquisition date and nature (Restricted Stock Vesting), and sale date (08/13/2025). It also states the seller’s representation that they lack undisclosed material adverse information and reports no sales in the prior three months. The form does not identify the named seller in the available fields.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	Citigroup Global Markets Inc. 390 Greenwich Street New York NY 10013	2158	412319.34	60454589	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	08/13/2025	Restricted Stock Vesting	Ascendis Pharma A/S			2158	08/13/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Ascendis Pharma (ASND) file in this Form 144?

The filing is a Form 144 notice reporting a proposed sale of securities under Rule 144: 2,158 ordinary shares to be sold on NASDAQ.

How many shares and what aggregate market value are reported?

The form reports 2,158 shares with an aggregate market value of 412,319.34.

When were the shares acquired and by what method?

The shares were acquired on 08/13/2025 via Restricted Stock Vesting, and the consideration is listed as Compensation.

When is the approximate date of the proposed sale?

The approximate sale date listed is 08/13/2025.

How many shares does Ascendis Pharma have outstanding per the filing?

The filing lists 60,454,589 shares outstanding.